Leap Therapeutics (NASDAQ:LPTX) Stock Rating Reaffirmed by HC Wainwright

Leap Therapeutics (NASDAQ:LPTX)‘s stock had its “buy” rating restated by HC Wainwright in a report issued on Tuesday, Benzinga reports. They presently have a $5.50 target price on the stock. HC Wainwright’s target price would suggest a potential upside of 123.58% from the company’s previous close.

Separately, Rodman & Renshaw initiated coverage on Leap Therapeutics in a research note on Friday, June 28th. They issued a “buy” rating and a $8.00 target price for the company. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Leap Therapeutics has a consensus rating of “Buy” and a consensus price target of $10.40.

Leap Therapeutics Trading Down 4.7 %

Shares of NASDAQ LPTX opened at $2.46 on Tuesday. Leap Therapeutics has a 12 month low of $1.24 and a 12 month high of $5.00. The firm has a market capitalization of $62.98 million, a price-to-earnings ratio of -1.03 and a beta of 0.31. The business has a 50-day moving average of $2.09 and a 200-day moving average of $2.56.

Leap Therapeutics (NASDAQ:LPTX) last issued its earnings results on Monday, May 13th. The company reported ($0.51) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.57) by $0.06. On average, analysts predict that Leap Therapeutics will post -1.66 earnings per share for the current year.

Institutional Trading of Leap Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Marshall Wace LLP lifted its position in Leap Therapeutics by 268.2% in the second quarter. Marshall Wace LLP now owns 79,758 shares of the company’s stock valued at $156,000 after purchasing an additional 58,094 shares during the last quarter. Key Client Fiduciary Advisors LLC raised its holdings in shares of Leap Therapeutics by 8.6% during the first quarter. Key Client Fiduciary Advisors LLC now owns 233,018 shares of the company’s stock valued at $620,000 after acquiring an additional 18,408 shares in the last quarter. Acadian Asset Management LLC raised its holdings in shares of Leap Therapeutics by 349.3% during the first quarter. Acadian Asset Management LLC now owns 282,413 shares of the company’s stock valued at $750,000 after acquiring an additional 219,563 shares in the last quarter. Simplify Asset Management Inc. raised its holdings in shares of Leap Therapeutics by 67.9% during the second quarter. Simplify Asset Management Inc. now owns 631,269 shares of the company’s stock valued at $1,237,000 after acquiring an additional 255,293 shares in the last quarter. Finally, Vanguard Group Inc. raised its holdings in shares of Leap Therapeutics by 111.7% during the first quarter. Vanguard Group Inc. now owns 867,708 shares of the company’s stock valued at $2,308,000 after acquiring an additional 457,904 shares in the last quarter. Institutional investors own 30.46% of the company’s stock.

Leap Therapeutics Company Profile

Leap Therapeutics, Inc, a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501.